S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(0.28%) $78.33
Gas
(0.23%) $2.15
Gold
(0.45%) $2 319.00
Silver
(1.78%) $27.17
Platinum
(-0.46%) $960.90
USD/EUR
(0.02%) $0.929
USD/NOK
(-0.04%) $10.87
USD/GBP
(0.00%) $0.797
USD/RUB
(0.00%) $91.45

实时更新: PharmaEngine, Inc. [4162.TWO]

交易所: TWO 部门: Healthcare 工业: Biotechnology
最后更新时间6 May 2024 @ 11:14

0.32% TWD 94.10

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 11:14):

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis...

Stats
今日成交量 184 444
平均成交量 1.04M
市值 13.52B
EPS TWD0 ( 2024-04-26 )
下一个收益日期 ( TWD0.550 ) 2024-07-24
Last Dividend TWD0 ( N/A )
Next Dividend TWD0 ( N/A )
P/E 49.27
ATR14 TWD0.127 (0.13%)

音量 相关性

長: 0.17 (neutral)
短: -0.59 (weak negative)
Signal:(46.394) Neutral

PharmaEngine, Inc. 相关性

10 最正相关
10 最负相关

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

PharmaEngine, Inc. 相关性 - 货币/商品

The country flag -0.66
( moderate negative )
The country flag 0.03
( neutral )
The country flag 0.00
( neutral )
The country flag -0.01
( neutral )
The country flag 0.51
( weak )

PharmaEngine, Inc. 财务报表

Annual 2023
营收: TWD767.67M
毛利润: TWD718.97M (93.66 %)
EPS: TWD1.910
FY 2023
营收: TWD767.67M
毛利润: TWD718.97M (93.66 %)
EPS: TWD1.910
FY 2022
营收: TWD654.38M
毛利润: TWD604.68M (92.41 %)
EPS: TWD2.22
FY 2021
营收: TWD654.84M
毛利润: TWD617.76M (94.34 %)
EPS: TWD2.93

Financial Reports:

No articles found.

PharmaEngine, Inc.

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。